Study: CanSino Covid-19 vaccine an effective booster shot with antibodies increasing 78-fold
KUCHING: Solution Group Bhd’s (Solution) wholly owned subsidiary Solution Biologics Sdn Bhd (SOLBIO), the Asean manufacturing partner for CanSino Biologics Inc’s (CanSino) single-dose vaccine, believes that the vaccine is an effective booster shot against the spread of Covid-19 variants.
Data from a recent Chinese clinical study has shown that taking a booster shot with CanSino’s single-dose Covid-19 vaccine (Convidecia vaccine) after receiving a two-dose inactivated vaccine is proven to be safe and able to effectively produce an immune response to the Covid-19 virus.
The study by Jiangsu Center of Disease Control published by MedRxiv before a peer review revealed that the Convidecia booster shot demonstrated an increase of at least 78-fold in average neutralising antibody levels, in comparison with a booster shot with the same inactivated vaccine showing 15.2fold increase in antibody levels.
The base for the study came from a randomised, controlled, observer-blinded trial of 300
participants aged between 18 and 59 years old who received one dose of Sinovac Biotech Ltd’s (Sinovac) CoronaVac in the past one to three months or two doses in the past three to six months.
The study then compared Sinovac’s CoronaVac with CanSino’s Convidecia as a
booster shot for safety and immune response.
“With the new data, we see that a booster dose of CanSino’s single-dose Covid-19 vaccine can help increase antibody responses among the study participants who had previously received one or two doses of inactivated vaccine,” Solution deputy group managing director Dato’ Dr. Mohd Nazlee Bin Kamal said.
“We hope that with the results of the study, the government will consider including CanSino’s Convidecia vaccine as part of the booster dose programme.
“We have the infrastructure through our Fill and Finish facility and the capacity ready to take on the rise in demand.
“We can provide the booster shots for Malaysia and at the same time, supply to the Asean region.”
Malaysia is considering booster shots to enhance the immune system against the virus beginning early October.
The supply agreement that SOLBIO signed with the Ministry of Health Malaysia (MOH) to supply 3.5 million doses of CanSino’s Convidecia vaccine will be fulfilled by November 2021, of which 300,000 doses were handed to the MOH last month.
“Total of 2.6 million doses will be delivered by end-October, with the entire supply of 3.5 million doses to be completed by November.”